A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms
Gastrointestinal Neoplasms

Interventions

DRUG: JNJ-89402638
DRUG: Bevacizumab
DRUG: FOLFOX
DRUG: FOLFIRI

Sponsor

Janssen Research & Development, LLC